Encompass Health (EHC) Expected to Post Quarterly Earnings on Wednesday

Encompass Health (NYSE:EHC) is expected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to post earnings of $1.36 per share and revenue of $1.60 billion for the quarter. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 10:00 AM ET.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was up 9.6% on a year-over-year basis. On average, analysts expect Encompass Health to post $6.08 EPS for the current fiscal year and $6.60 EPS for the next fiscal year.

Encompass Health Stock Performance

Shares of EHC opened at $121.59 on Wednesday. Encompass Health has a one year low of $92.77 and a one year high of $129.96. The company has a 50-day moving average of $122.37 and a two-hundred day moving average of $112.01. The stock has a market cap of $11.99 billion, a price-to-earnings ratio of 19.80, a PEG ratio of 2.46 and a beta of 0.74. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.19.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st were issued a dividend of $0.21 per share. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Thursday, October 1st. Encompass Health’s dividend payout ratio (DPR) is presently 13.68%.

Insider Transactions at Encompass Health

In other news, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.47, for a total value of $21,724,879.56. Following the transaction, the chief executive officer owned 267,814 shares in the company, valued at $33,602,622.58. This represents a 39.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Darby sold 4,858 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $121.09, for a total transaction of $588,255.22. Following the completion of the sale, the executive vice president directly owned 75,041 shares of the company’s stock, valued at $9,086,714.69. This trade represents a 6.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 186,912 shares of company stock valued at $23,434,845 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Encompass Health from a “buy” rating to a “hold” rating in a research report on Saturday. Raymond James Financial set a $150.00 price objective on shares of Encompass Health in a research note on Monday, September 28th. Barclays lifted their price objective on shares of Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Truist Financial boosted their target price on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, TD Cowen boosted their target price on shares of Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $148.50.

Encompass Health Company Profile

Encompass Health Corporation (NYSE:EHC) is a healthcare services company that operates inpatient rehabilitation hospitals in the United States and Puerto Rico. Its hospitals provide intensive rehabilitation to patients recovering from conditions such as stroke, brain and spinal cord injuries, neurological disorders, amputations, hip fractures and other serious illnesses or injuries.

The company’s services typically include nursing care, physical therapy, occupational therapy, speech and language therapy, respiratory therapy and medical management.